Compare AbbVie Inc (ABBV) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Dollar General Corp. — how do they compare? AbbVie Inc trades at $253.74 (market cap $449.91B), while Dollar General Corp. trades at $116.04 (market cap $25.46B). The key difference: AbbVie Inc is far larger — about 17.7× Dollar General Corp.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | DG | |
|---|---|---|
Market Cap | $449.91B | $25.46B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $156.26 |
52-Week Low | $184.85 | $95.94 |
Enterprise Value | $513.38B | $39.91B |
Dividend Yield | 2.72% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Dollar General (DG) trades at $115.43, down 2.32% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.00 surpassing the $1.89 estimate. Fundamentals reveal steady revenue growth to $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive cash flow trends and a manageable debt-to-asset ratio of 20.03% support financial health.
The investment outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating with a $128.91 price target, implying ~12% upside. Key opportunities include margin expansion initiatives and the DG Media Network, while risks involve consumer spending sensitivity and competitive pressures. The current valuation at a P/E of 16.45 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
